Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
NeoGenomics ( (NEO) ) has issued an update.
NeoGenomics announced the retirement of CEO Chris Smith, effective April 1, 2025, who will continue as a special advisor. Tony Zook, an experienced healthcare executive, will succeed Smith as CEO, bringing expertise in commercial operations and strategic leadership. Under Smith’s leadership, NeoGenomics transformed significantly, achieving double-digit revenue growth and improving its financial position. Zook’s appointment is expected to sustain the company’s growth trajectory and reinforce its leadership in oncology testing.
More about NeoGenomics
NeoGenomics, Inc. is a leading cancer diagnostics company specializing in cancer genetics testing and information services. It offers a comprehensive oncology-focused testing menu, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing. Headquartered in Fort Myers, FL, the company operates CAP-accredited and CLIA-certified laboratories throughout the US and a full-service laboratory in Cambridge, UK.
YTD Price Performance: 12.86%
Average Trading Volume: 726,341
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.39B
Learn more about NEO stock on TipRanks’ Stock Analysis page.
